S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.29
    -0.25 (-1.28%)

    Market Cap: $1.74B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +11.09%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.47
    Range$-0.58 - $-0.31
    10 analysts
    EPS Revisions
    2
    0
    7d
    2
    4
    30d
    EPS Estimate Drift
    90d ago$-0.38+19.1%
    60d ago$-0.40+15.9%
    30d ago$-0.39+17.4%
    7d ago$-0.45+3.4%
    Current$-0.47
    Revenue Consensus
    $83M
    Range$79M - $86M
    11 analysts
    Dec 31, 2026
    EPS Consensus$-0.44
    Range$-0.75 - $-0.15
    10 analysts
    Revenue Consensus
    $84M
    Range$72M - $103M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.47---
    Jun 26
    		$-0.55$-0.45-22.22%Miss+33.7%
    Mar 26
    		$-0.48$-0.59+18.64%Beat+51.0%
    Dec 25
    		$-0.78$-0.64-21.88%Miss+29.1%
    Sep 25
    		$-0.70$-0.71+1.41%Beat+28.6%
    Jun 25
    		$-0.83$-1.01+17.82%Beat-3.7%
    Mar 25
    		$-0.98$-1.27+22.83%Beat-15.3%
    Dec 24
    		$-1.10$-0.23-380.56%Miss-10.0%
    Sep 24
    		$-0.98$-1.06+7.55%Beat-34.2%
    Jun 24
    		$-0.80$-0.91+12.09%Beat-25.0%
    Mar 24
    		$-0.85$-0.98+13.27%Beat-44.1%
    Dec 23
    		$-1.00$-0.97-3.09%Miss-61.3%
    Sep 23
    		$-0.73$-0.80+8.75%Beat-25.9%
    Jun 23
    		$-0.64$-0.75+14.67%Beat-3.2%
    Mar 23
    		$-0.59$-0.61+3.28%Beat+6.3%
    Dec 22
    		$-0.62$-0.65+4.62%Beat-134.3%
    Sep 22
    		$-0.58$-0.63+7.94%Beat-45.0%
    Jun 22
    		$-0.62$-0.62+0.00%Beat-40.9%
    Mar 22
    		$-0.63$-0.68+7.35%Beat-16.7%
    Dec 21
    		$1.81$0.28+546.43%Beat+511.4%
    Sep 21
    		$-0.40$-0.57+29.82%Beat+13.0%
    Jun 21
    		$-0.44$-0.73+39.73%Beat-4.8%
    Mar 21
    		$-0.54$-0.64+15.63%Beat+3.6%
    Dec 20
    		$-0.44$-0.49+10.20%Beat+0.0%
    Sep 20
    		$-0.46$-0.43-6.98%Miss-12.2%
    Jun 20
    		$-0.42$-0.44+4.55%Beat+10.6%
    Mar 20
    		$-0.56$-0.51-9.80%Miss-5.7%
    Dec 19
    		$-0.44$-0.43-2.33%Miss+37.1%
    Sep 19
    		$-0.41$-0.48+14.58%Beat+39.7%
    Jun 19
    		$-0.47$-0.47+0.00%Beat+36.5%
    Mar 19
    		$-0.53$-0.55+3.64%Beat+32.9%
    Dec 18
    		$-0.70$-0.67-4.48%Miss+12.5%
    Sep 18
    		$-0.68$-0.76+10.53%Beat+0.0%
    Jun 18
    		$-0.74$-0.89+16.85%Beat-5.7%
    Mar 18
    		$-0.79$-0.95+16.84%Beat-11.3%
    Dec 17
    		$-0.80$-0.78-2.56%Miss-35.6%
    Sep 17
    		$-0.68$-0.82+17.07%Beat+19.0%
    Jun 17
    		$-0.70$-0.82+14.63%Beat-
    Mar 17
    		$-0.71$-0.71+0.00%Beat-
    Dec 16
    		$-0.59$-0.73+19.18%Beat-
    Sep 16
    		$-0.84$-0.82-2.44%Miss-

    Key Metrics

    Valuation
    P/E Ratio-7.69EV/EBITDA-105.26x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-87.50%Operating Margin-54.90%
    ROE-255.90%ROIC-60.82%
    Financial Health
    Debt/Equity16.17xInterest CoverageN/A
    Current Ratio6.77xQuick Ratio6.44x
    Trading Statistics
    Beta0.37Avg Volume1.33M
    52-Week High$25.5952-Week Low$12.99

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.87
    SMA 20$19.85
    SMA 50$20.88
    SMA 200$20.90
    EMA 10$19.77
    EMA 20$19.95
    EMA 50$20.34
    EMA 200$19.87

    MACD

    Line: -0.26Signal: -0.27Hist: 0.01

    ADX

    ADX: 27.8+DI: 13.9-DI: 25.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down28.0
    PSAR$20.53

    Bollinger Bands

    Upper Band$20.71
    Lower Band$18.99
    %B Position868%(Upper)
    Band Width0.18

    RSI (14-Day)

    Neutral
    42.5

    Momentum Oscillators

    Stoch %K41.0
    Stoch %D51.7
    Williams %R-77.1
    ROC (10d)-2.4%
    Momentum-0.47
    CCI (20d)-123.0
    MFI (14d)39.1

    Volatility Measures

    ATR (14d)$0.88(4.5%)
    StdDev (20d)0.43
    Hist Vol40.7%(High)

    Volume Flow

    VWAP$19.25
    OBV16.2M
    AD Line-22.4M
    CMF (20d)0.057

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.1x
    VWMA (20d)$19.80

    Pivot Points

    R3$20.48
    R2$20.26
    R1$19.90
    Pivot Point$19.68
    S1$19.32
    S2$19.11
    S3$18.75

    Advanced Oscillators

    TSI-8.48
    Ultimate Osc48.5
    KST-56.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$72.79M$64.86M$68.48M$45.87M$37.96M$20.04M$7.68M$12.50M$3.50M$0$536,000$0
    Cost of Revenue$3.21M$2.63M$2.71M$2.10M$1.28M$885,000$826,000$0$0$0$268,000$0
    Gross Profit$69.58M$62.23M$65.78M$43.77M$36.68M$19.16M$6.85M$12.50M$3.50M$0$268,000$0
    Operating Expenses$109.58M$96.43M$128.32M$101.20M$106.03M$102.91M$103.22M$102.08M$77.72M$79.51M$77.91M$56.35M
    R&D$68.04M$58.84M$78.64M$56.28M$62.23M$61.64M$65.53M$70.97M$48.66M$56.49M$55.13M$39.09M
    SG&A$41.54M$37.59M$49.93M$44.92M$43.80M$41.03M$37.69M$31.11M$29.06M$23.02M$22.78M$17.27M
    Operating Income$-39,995,000$-34,202,000$-62,548,000$-57,426,000$-69,353,000$-83,757,000$-96,365,000$-89,577,000$-74,216,000$-79,514,000$-77,906,000$-56,355,000
    Interest Income$3.75M$3.56M$4.33M$5.27M$5.95M$7.18M$7.11M$5.44M$6.28M$7.26M$5.55M$5.34M
    Interest Expense$557,000$11.85M$25.73M$0$4,000$8.05M$-124,000$23,000$45,000$55,000$63,000$70,000
    Income Before Tax$-49,363,000$-42,673,000$-68,014,000$-60,715,000$-71,847,000$-84,846,000$-94,169,000$-84,126,000$-68,063,000$-72,400,000$-72,473,000$-51,146,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-49,363,000$-42,673,000$-68,014,000$-60,715,000$-71,847,000$-84,846,000$-94,169,000$-84,126,000$-68,063,000$-72,400,000$-72,473,000$-51,146,000
    EBITDA$-52,950,000$-35,190,000$-48,140,000$-68,335,000$-80,949,000$-87,465,000$-104,311,000$-92,603,000$-77,951,000$-83,422,000$-81,420,000$-60,080,000
    EBIT$-52,552,000$-34,388,000$-46,612,000$-65,984,000$-77,793,000$-83,978,000$-101,401,000$-89,545,000$-74,302,000$-79,601,000$-77,961,000$-56,421,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNDX

    News

    Trails Edge Capital Partners LP Buys Shares of 1,110,000 Syndax Pharmaceuticals, Inc. $SNDX

    Trails Edge Capital Partners LP has acquired a new stake of 1,110,000 shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the second quarter, valued at approximately $24.26 billion. This investment makes Syndax Pharmaceuticals the 12th largest position in Trails Edge Capital Partners LP's portfolio, representing about 3.9% of their total holdings. Other institutional investors also increased their stakes, while several insiders, including the CEO and CMO, sold significant amounts of company stock.

    MarketBeat•8/26/26•
    Neutral

    Elmind Capital LP Buys Shares of 1,855,000 Syndax Pharmaceuticals, Inc. $SNDX

    Elmind Capital LP has acquired a new position of 1,855,000 shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), valued at approximately $40.55 billion, making it their second largest holding. Other institutional investors like Hsbc Holdings PLC and Mirae Asset Global Investments Co. Ltd. also adjusted their stakes in the company. Syndax Pharmaceuticals recently reported an EPS of ($0.55), missing analyst estimates, and has a current market cap of $1.77 billion.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

    Parkman Healthcare Partners LLC has acquired 877,256 shares of Syndax Pharmaceuticals, Inc. (SNDX) valued at approximately $19.2 million, making it their 19th largest holding and representing 0.99% of Syndax's outstanding stock. Other institutional investors also increased or initiated positions in Syndax, despite the company reporting a quarterly loss that missed analyst estimates and insider stock sales totaling $2.1 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $41.55.

    MarketBeat•8/25/26•
    Neutral

    Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX

    Algert Global LLC increased its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 13.2% in the second quarter, bringing its total holdings to 1,051,465 shares valued at $22.98 million. Other institutional investors also adjusted their positions in the company, while several Wall Street analysts maintained "buy" or "overweight" ratings, with a consensus price target of $41.55. Recent insider transactions include sales by the CEO and CMO, and the company reported a quarterly EPS of ($0.55), missing consensus estimates.

    MarketBeat•8/25/26•
    Neutral

    SYNDAX PHARMACEUTICALS, INC. : UBS CUTS TARGET PRICE TO $33 FROM $37

    UBS has cut its target price for Syndax Pharmaceuticals Inc. (SNDX.O) from $37 to $33. This update was reported by Reuters on August 21, 2026, and is available on Bitget News.

    Bitget•8/22/26•
    Bearish

    Frequently Asked Questions About SNDX

    Does SNDX pay dividends?
    Syndax Pharmaceuticals Inc (SNDX) does not currently pay a regular dividend.
    What is SNDX's market cap?
    Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $1.74B with a current stock price of $19.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In